Cumberland Pharmaceuticals Inc. (CPIX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription drugs in hospital acute care, gastroenterology, and oncology. The company operates as a single segment. As of May 5, 2026, there were 14,983,107 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $9.13 million | $11.71 million |
| Operating Loss | $(3.13) million | $1.29 million (Income) |
| Net Loss | $(3.29) million | $1.25 million (Income) |
| Diluted EPS | $(0.22) | $0.08 |
| Cash and Equivalents | $11.01 million | $15.11 million (End of Q1 2025) |
| Working Capital | $(1.70) million | $0.32 million (Dec 31, 2025) |
| Debt Outstanding | $5.24 million | $5.24 million |
| Operating Cash Flow | $0.39 million | $3.90 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased by $2.58 million (22%) compared to Q1 2025. This decline is primarily attributed to the absence of a $3.0 million milestone payment received in Q1 2025 related to Vibativ's approval in China. Additionally, Kristalose revenue dropped significantly due to timing of shipments and generic substitution.
- Product Performance: Sancuso revenue increased to $2.93 million (up $0.67 million) and Vibativ revenue rose to $2.12 million (up $0.74 million) due to higher sales volumes. Talicia generated $1.92 million in revenue following its launch in late 2025.
- Profitability: The company reported a net loss of $3.29 million, a swing of $4.54 million from the net income of $1.25 million in the prior year. Operating expenses increased by $1.84 million, driven largely by higher selling and marketing costs associated with the Talicia launch and increased amortization.
- Liquidity: Working capital turned negative to $(1.70) million from a positive $0.32 million at year-end 2025. Cash and cash equivalents decreased by $0.44 million during the quarter.
Guidance, Outlook, and Material Events
- Strategic Transaction: On April 22, 2026, Cumberland entered into a definitive agreement to sell its portfolio of FDA-approved commercial products (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ) to an affiliate of Apotex Inc. for $100 million in cash. The transaction is subject to shareholder approval.
- Post-Transaction Strategy: Following the sale, Cumberland intends to retain its development programs, including the ifetroban product candidate, and its majority-owned subsidiary, Cumberland Emerging Technologies (CET), transitioning to a development-stage biopharmaceutical organization.
- Regulatory Updates: The FDA granted Fast Track Designation for ifetroban (Duchenne muscular dystrophy) in Q1 2026. An expanded indication for Caldolor (postoperative pain) was approved in April 2026.
- Risks: The company is assessing the impact of new tariffs on patented pharmaceuticals issued in April 2026. Vaprisol revenue remains negligible as the company transitions to a new manufacturing partner pending FDA approval.
Investor Verification Checklist
- Transaction Closing: Verify the status of shareholder approval and closing conditions for the $100 million Apotex asset purchase agreement.
- Inventory Reimbursement: Confirm the terms and timing of the $9 million one-time inventory reimbursement payment from Apotex due one year post-closing.
- Transition Services: Review the details of the transition services agreement, including the $150,000 monthly fee and duration.
- Debt Covenants: Monitor compliance with the Minimum Fixed Charge Coverage Ratio and Borrowing Base Requirements under the amended Pinnacle Bank credit facility.
- Product Pipeline: Track the progress of the ifetroban clinical trials and regulatory interactions following the Fast Track designation.